With the US still battling the opioid epidemic, the most widely-used overdose reversal agent – Emergent BioSolutions’ Narcan – can now be bought over the counter at pharma
Pear Therapeutics already has three FDA-approved prescription digital therapeutics (DTx) on the market – but it seems that isn’t enough to ensure a stable financial positi
Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis' mavoglurant, in clinical trials for cocaine use disorder (CU
Addiction treatment specialist Spero Health has expanded an agreement to use Pear Therapeutics’ prescription digital therapeutics (DTx) in its network of US clinics.
Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds for the digital hea
Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea